{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:22:35Z","timestamp":1793852555828,"version":"4.6.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003790","name":"Hiroshima University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003790","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Anesth"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Malignant hyperthermia (MH) is a rare, life-threatening inherited disorder triggered by volatile inhalational anesthetics and\/or the depolarizing muscle relaxant suxamethonium. In susceptible individuals, calcium release from the sarcoplasmic reticulum in the skeletal muscle becomes abnormally accelerated, leading to a hypermetabolic state. Early signs of MH include unexplained hypercarbia (end-tidal carbon dioxide\u2009&gt;\u200955\u00a0mm Hg), tachycardia, and muscle rigidity, particularly in the masseter. Rapid increases in core temperature (&gt;\u20090.5\u00a0\u00b0C\/15\u00a0min, with temperatures often exceeding 40\u00a0\u00b0C) are typical. With progression, respiratory and metabolic acidosis, arrhythmias, cola-colored urine (myoglobinuria), elevated serum potassium, and tented T-waves may develop, potentially leading to cardiac arrest or multiorgan failure. The Japanese Society of Anesthesiologists\u2019 guidelines for the management of MH in 2025 (Japanese version) emphasize the importance of early recognition and immediate intervention. The essential steps include discontinuing triggering agents, administering intravenous dantrolene (initially 1\u20132\u00a0mg\/kg), aggressive cooling of the body, and managing complications, such as hyperkalemia and acidosis. On the basis of international standards, a higher initial dose of dantrolene is recommended. Preoperative assessment of MH risk should include history taking for anesthetic complications, a family history suggestive of MH susceptibility, signs of congenital myopathies, and careful anesthetic planning using non-triggering agents. Genetic testing and muscle biopsy may aid in the diagnosis but are not definitive in all cases. The Japanese translation of these guidelines has been posted on the following website:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/anesth.or.jp\/files\/pdf\/guideline_akuseikounetsu\" ext-link-type=\"uri\">https:\/\/anesth.or.jp\/files\/pdf\/guideline_akuseikounetsu<\/jats:ext-link>\n                    . pdf.\n                  <\/jats:p>","DOI":"10.1007\/s00540-025-03647-y","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:28:43Z","timestamp":1767850123000},"page":"4-12","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["JSA guideline for management of malignant hyperthermia in 2025"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1997-082X","authenticated-orcid":false,"given":"Yasuo M.","family":"Tsutsumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nagasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Mukaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuko","family":"Ichihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimichi","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The M. H. Management Guideline Working Group of Safety Committee of the Japanese Society of Anesthesiologists","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"3647_CR1","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/anae.15317","volume":"76","author":"PM Hopkins","year":"2021","unstructured":"Hopkins PM, Girard T, Dalay S, Jenkins B, Thacker A, Patteril M, et al. Malignant hyperthermia 2020: guideline from the Association of Anaesthetists. Anaesthesia. 2021;76:655\u201364.","journal-title":"Anaesthesia"},{"key":"3647_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.bja.2024.09.022","volume":"134","author":"KPE Glahn","year":"2025","unstructured":"Glahn KPE, Girard T, Hellblom A, Hopkins PM, Johannsen S, Ruffert H, et al. Recognition and management of malignant hyperthermia crisis: updated 2024 guideline from the European Malignant Hyperthermia Group. Br J Anaesth. 2025;134:221\u20133.","journal-title":"Br J Anaesth"},{"key":"3647_CR3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.bja.2020.09.029","volume":"126","author":"H Ruffert","year":"2021","unstructured":"Ruffert H, Bastian B, Bendixen D, Girard T, Heiderich S, Hellblom A, et al. Consensus guidelines on perioperative management of malignant hyperthermia suspected or susceptible patients from the European Malignant Hyperthermia Group. Br J Anaesth. 2021;126:120\u201330.","journal-title":"Br J Anaesth"},{"key":"3647_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.bja.2020.04.089","volume":"125","author":"KPE Glahn","year":"2020","unstructured":"Glahn KPE, Bendixen D, Girard T, Hopkins PM, Johannsen S, Ruffert H, et al. Availability of dantrolene for the management of malignant hyperthermia crises: European Malignant Hyperthermia Group guidelines. Br J Anaesth. 2020;125:133\u201340.","journal-title":"Br J Anaesth"},{"key":"3647_CR5","unstructured":"Rosenberg H, Sambuughin N, Riazi S, Dirksen R. Malignant Hyperthermia Susceptibility. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews((R)). Seattle (WA)1993\u20132024."},{"key":"3647_CR6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/cge.14475","volume":"105","author":"Z Cong","year":"2024","unstructured":"Cong Z, Wan T, Wang J, Feng L, Cao C, Li Z, et al. Epidemiological and clinical features of malignant hyperthermia: a scoping review. Clin Genet. 2024;105:233\u201342.","journal-title":"Clin Genet"},{"key":"3647_CR7","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1213\/ANE.0000000000005837","volume":"135","author":"S Otsuki","year":"2022","unstructured":"Otsuki S, Miyoshi H, Mukaida K, Yasuda T, Nakamura R, Tsutsumi YM. Age-specific clinical features of pediatric malignant hyperthermia: a review of 187 cases over 60 years in Japan. Anesth Analg. 2022;135:128\u201335.","journal-title":"Anesth Analg"},{"key":"3647_CR8","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/8340209","volume":"2023","author":"Y Toyota","year":"2023","unstructured":"Toyota Y, Kondo T, Shorin D, Sumii A, Kido K, Watanabe T, et al. Rapid dantrolene administration with body temperature monitoring is associated with decreased mortality in Japanese malignant hyperthermia events. Biomed Res Int. 2023;2023:8340209.","journal-title":"Biomed Res Int"},{"key":"3647_CR9","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1093\/hmg\/ddac145","volume":"31","author":"JJ Johnston","year":"2022","unstructured":"Johnston JJ, Dirksen RT, Girard T, Hopkins PM, Kraeva N, Ognoon M, et al. Updated variant curation expert panel criteria and pathogenicity classifications for 251 variants for RYR1-related malignant hyperthermia susceptibility. Hum Mol Genet. 2022;31:4087\u201393.","journal-title":"Hum Mol Genet"},{"key":"3647_CR10","doi-asserted-by":"publisher","first-page":"e461","DOI":"10.1016\/j.bja.2019.06.010","volume":"123","author":"O Mungunsukh","year":"2019","unstructured":"Mungunsukh O, Deuster P, Muldoon S, O\u2019Connor F, Sambuughin N. Estimating prevalence of malignant hyperthermia susceptibility through population genomics data. Br J Anaesth. 2019;123:e461\u20133.","journal-title":"Br J Anaesth"},{"key":"3647_CR11","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8845129","volume":"2021","author":"T Watanabe","year":"2021","unstructured":"Watanabe T, Miyoshi H, Noda Y, Narasaki S, Morio A, Toyota Y, et al. Effects of remimazolam and propofol on Ca(2+) regulation by ryanodine receptor 1 with malignant hyperthermia mutation. Biomed Res Int. 2021;2021:8845129.","journal-title":"Biomed Res Int"},{"key":"3647_CR12","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.bja.2018.07.008","volume":"121","author":"JR Lopez","year":"2018","unstructured":"Lopez JR, Kaura V, Diggle CP, Hopkins PM, Allen PD. Malignant hyperthermia, environmental heat stress, and intracellular calcium dysregulation in a mouse model expressing the p.G2435R variant of RYR1. Br J Anaesth. 2018;121:953\u201361.","journal-title":"Br J Anaesth"},{"key":"3647_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/genes14112009","author":"H Miyoshi","year":"2023","unstructured":"Miyoshi H, Otsuki S, Mukaida K, Kido K, Sumii A, Ikeda T, et al. Effects of remimazolam on intracellular calcium dynamics in myotubes derived from patients with malignant hyperthermia and functional analysis of type 1 ryanodine receptor gene variants. Genes. 2023. https:\/\/doi.org\/10.3390\/genes14112009.","journal-title":"Genes"},{"key":"3647_CR14","doi-asserted-by":"publisher","first-page":"C1094","DOI":"10.1152\/ajpcell.00173.2004","volume":"287","author":"RG Weiss","year":"2004","unstructured":"Weiss RG, O\u2019Connell KM, Flucher BE, Allen PD, Grabner M, Dirksen RT. Functional analysis of the R1086H malignant hyperthermia mutation in the DHPR reveals an unexpected influence of the III-IV loop on skeletal muscle EC coupling. Am J Physiol Cell Physiol. 2004;287:C1094\u2013102.","journal-title":"Am J Physiol Cell Physiol"},{"key":"3647_CR15","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1213\/01.ane.0000196515.06945.fb","volume":"102","author":"I Kwetny","year":"2006","unstructured":"Kwetny I, Finucane BT. Negative arterial to end-tidal carbon dioxide gradient: an additional sign of malignant hyperthermia during desflurane anesthesia. Anesth Analg. 2006;102:815\u20137.","journal-title":"Anesth Analg"},{"key":"3647_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1093\/bja\/47.1.62","volume":"47","author":"GG Harrison","year":"1975","unstructured":"Harrison GG. Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. Br J Anaesth. 1975;47:62\u20135.","journal-title":"Br J Anaesth"},{"key":"3647_CR17","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/00000542-198204000-00005","volume":"56","author":"ME Kolb","year":"1982","unstructured":"Kolb ME, Horne ML, Martz R. Dantrolene in human malignant hyperthermia. Anesthesiology. 1982;56:254\u201362.","journal-title":"Anesthesiology"},{"key":"3647_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0031-6997(24)01312-7","volume":"49","author":"R Zucchi","year":"1997","unstructured":"Zucchi R, Ronca-Testoni S. The sarcoplasmic reticulum Ca2+ channel\/ryanodine receptor: modulation by endogenous effectors, drugs and disease states. Pharmacol Rev. 1997;49:1\u201351.","journal-title":"Pharmacol Rev"},{"key":"3647_CR19","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/j.1365-2044.2004.03658.x","volume":"59","author":"T Krause","year":"2004","unstructured":"Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F. Dantrolene\u2013a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004;59:364\u201373.","journal-title":"Anaesthesia"},{"key":"3647_CR20","unstructured":"Japanese Society of Anesthesiologists Safety Committee, Pharmaceutical Guidelines Revision Working Group. Guidelines for the Use of Anesthetics and Anesthesia-Related Drugs, 3rd Edition, 4th Revision, Section VI: Muscle Relaxants and Antagonists. 2019:149\u201350."},{"key":"3647_CR21","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1213\/ANE.0000000000000062","volume":"118","author":"M Visoiu","year":"2014","unstructured":"Visoiu M, Young MC, Wieland K, Brandom BW. Anesthetic drugs and onset of malignant hyperthermia. Anesth Analg. 2014;118:388\u201396.","journal-title":"Anesth Analg"},{"key":"3647_CR22","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1213\/ANE.0b013e3182937d8b","volume":"118","author":"S Riazi","year":"2014","unstructured":"Riazi S, Larach MG, Hu C, Wijeysundera D, Massey C, Kraeva N. Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands. Anesth Analg. 2014;118:381\u20137.","journal-title":"Anesth Analg"},{"key":"3647_CR23","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/00000542-199404000-00008","volume":"80","author":"MG Larach","year":"1994","unstructured":"Larach MG, Localio AR, Allen GC, Denborough MA, Ellis FR, Gronert GA, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology. 1994;80:771\u20139.","journal-title":"Anesthesiology"},{"key":"3647_CR24","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1097\/ALN.0b013e31818958e5","volume":"109","author":"RS Litman","year":"2008","unstructured":"Litman RS, Flood CD, Kaplan RF, Kim YL, Tobin JR. Postoperative malignant hyperthermia: an analysis of cases from the North American Malignant Hyperthermia Registry. Anesthesiology. 2008;109:825\u20139.","journal-title":"Anesthesiology"},{"key":"3647_CR25","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1177\/0310057X1204000315","volume":"40","author":"C Jones","year":"2012","unstructured":"Jones C, Bennett K, Kim TW, Bulger TF, Pollock N. Preparation of Datex-Ohmeda Aestiva and Aisys anaesthetic machines for use in malignant hyperthermia susceptible patients. Anaesth Intensive Care. 2012;40:490\u20137.","journal-title":"Anaesth Intensive Care"},{"key":"3647_CR26","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00540-012-1347-0","volume":"26","author":"T Migita","year":"2012","unstructured":"Migita T, Mukaida K, Yasuda T, Hamada H, Kawamoto M. Calcium channel blockers are inadequate for malignant hyperthermia crisis. J Anesth. 2012;26:579\u201384.","journal-title":"J Anesth"},{"key":"3647_CR27","doi-asserted-by":"crossref","unstructured":"Burkman JM, Posner KL, Domino KB. Analysis of the clinical variables associated with recrudescence after malignant hyperthermia reactions. Anesthesiology. 2007;106:901\u20136; quiz 1077\u20138.","DOI":"10.1097\/01.anes.0000265148.86566.68"},{"key":"3647_CR28","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1213\/ANE.0b013e3182a8fad0","volume":"118","author":"P Nelson","year":"2014","unstructured":"Nelson P, Litman RS. Malignant hyperthermia in children: an analysis of the North American malignant hyperthermia registry. Anesth Analg. 2014;118:369\u201374.","journal-title":"Anesth Analg"},{"key":"3647_CR29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/bja\/aev225","volume":"115","author":"PM Hopkins","year":"2015","unstructured":"Hopkins PM, Ruffert H, Snoeck MM, Girard T, Glahn KP, Ellis FR, et al. European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility. Br J Anaesth. 2015;115:531\u20139.","journal-title":"Br J Anaesth"},{"key":"3647_CR30","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/00000542-199803000-00006","volume":"88","author":"GC Allen","year":"1998","unstructured":"Allen GC, Larach MG, Kunselman AR. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. Anesthesiology. 1998;88:579\u201388.","journal-title":"Anesthesiology"},{"key":"3647_CR31","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1152\/physrev.00040.2008","volume":"89","author":"M Endo","year":"2009","unstructured":"Endo M. Calcium-induced calcium release in skeletal muscle. Physiol Rev. 2009;89:1153\u201376.","journal-title":"Physiol Rev"},{"key":"3647_CR32","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s005400050002","volume":"14","author":"S Oku","year":"2000","unstructured":"Oku S, Mukaida K, Nosaka S, Sai Y, Maehara Y, Yuge O. Comparison of the in vitro caffeine-halothane contracture test with the Ca-induced Ca release rate test in patients suspected of having malignant hyperthermia susceptibility. J Anesth. 2000;14:6\u201313.","journal-title":"J Anesth"},{"key":"3647_CR33","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1097\/00000542-200606000-00008","volume":"104","author":"CA Ibarra Moreno","year":"2006","unstructured":"Ibarra Moreno CA, Wu S, Murayama K, Minami N, Ichihara Y, Kikuchi H, et al. Malignant hyperthermia in Japan: mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing. Anesthesiology. 2006;104:1146\u201354.","journal-title":"Anesthesiology"},{"key":"3647_CR34","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/343559a0","volume":"343","author":"DH MacLennan","year":"1990","unstructured":"MacLennan DH, Duff C, Zorzato F, Fujii J, Phillips M, Korneluk RG, et al. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature. 1990;343:559\u201361.","journal-title":"Nature"},{"key":"3647_CR35","unstructured":"European Malignant Hyperthermia Group. Diagnostic mutations. https:\/\/www.emhg.org\/diagnostic-mutations. Accessed Aug 7. 2024."},{"key":"3647_CR36","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1213\/ANE.0000000000000063","volume":"118","author":"KM Stowell","year":"2014","unstructured":"Stowell KM. DNA testing for malignant hyperthermia: the reality and the dream. Anesth Analg. 2014;118:397\u2013406.","journal-title":"Anesth Analg"},{"key":"3647_CR37","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1097\/ALN.0000000000002813","volume":"131","author":"CA Ibarra Moreno","year":"2019","unstructured":"Ibarra Moreno CA, Hu S, Kraeva N, Schuster F, Johannsen S, Rueffert H, et al. An assessment of penetrance and clinical expression of malignant hyperthermia in individuals carrying diagnostic ryanodine receptor 1 gene mutations. Anesthesiology. 2019;131:983\u201391.","journal-title":"Anesthesiology"},{"key":"3647_CR38","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1001\/jama.286.2.168","volume":"286","author":"JR Tobin","year":"2001","unstructured":"Tobin JR, Jason DR, Challa VR, Nelson TE, Sambuughin N. Malignant hyperthermia and apparent heat stroke. JAMA. 2001;286:168\u20139.","journal-title":"JAMA"},{"key":"3647_CR39","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/jmedgenet-2019-106461","volume":"57","author":"L Gardner","year":"2020","unstructured":"Gardner L, Miller DM, Daly C, Gupta PK, House C, de Roiz Sa D, et al. Investigating the genetic susceptibility to exertional heat illness. J Med Genet. 2020;57:531\u201341.","journal-title":"J Med Genet"},{"key":"3647_CR40","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.nmd.2013.03.008","volume":"23","author":"N Dlamini","year":"2013","unstructured":"Dlamini N, Voermans NC, Lillis S, Stewart K, Kamsteeg EJ, Drost G, et al. Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis. Neuromuscul Disord. 2013;23:540\u20138.","journal-title":"Neuromuscul Disord"},{"key":"3647_CR41","doi-asserted-by":"publisher","DOI":"10.5812\/aapm-132088","volume":"13","author":"P Radkowski","year":"2023","unstructured":"Radkowski P, Suren L, Podhorodecka K, Harikumar S, Jamrozik N. A review on the anesthetic management of patients with neuromuscular diseases. Anesth Pain Med. 2023;13:e132088.","journal-title":"Anesth Pain Med"},{"key":"3647_CR42","doi-asserted-by":"publisher","first-page":"220","DOI":"10.17085\/apm.22260","volume":"18","author":"HS Yang","year":"2023","unstructured":"Yang HS, Choi JM, In J, Sung TY, Kim YB, Sultana S. Current clinical application of dantrolene sodium. Anesth Pain Med. 2023;18:220\u201332.","journal-title":"Anesth Pain Med"},{"key":"3647_CR43","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1007\/s00540-018-2526-4","volume":"32","author":"S Otsuki","year":"2018","unstructured":"Otsuki S, Yasuda T, Mukaida K, Noda Y, Kanzaki R, Miyoshi H, et al. Myotoxicity of local anesthetics is equivalent in individuals with and without predisposition to malignant hyperthermia. J Anesth. 2018;32:616\u201323.","journal-title":"J Anesth"}],"container-title":["Journal of Anesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00540-025-03647-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00540-025-03647-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00540-025-03647-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T18:38:26Z","timestamp":1769884706000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00540-025-03647-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3647"],"URL":"https:\/\/doi.org\/10.1007\/s00540-025-03647-y","relation":{},"ISSN":["0913-8668","1438-8359"],"issn-type":[{"value":"0913-8668","type":"print"},{"value":"1438-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Keiko Mukaida: Affiliated with an endowed course in Higashihiroshima City, Hiroshima Prefecture, and received a salary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}